Press Releases

 
Press Releases
  Date Title View
Aug 14, 2015
Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S. Operating Cash Burn for Second Quarter of 2015 Reduced by 68% From Second Quarter of 2014 -- Company to Host Business Update Conference Call on Wednesday, August 19, 2015 -- WALTHAM, Mass., Aug. 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. ...
Aug 13, 2015
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering. The company is offering 2,315,654 Series A units, each c...
Aug 12, 2015
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the of...
Jul 27, 2015
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT® automated immunoassay analyzer will be presented at the 2015 Ame...
Jul 15, 2015
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that it has paid off its secured term loan facility with General Electric Capital Corporation and Comerica Bank. The secured term loan in the aggregate principal amount of $10 million was funded ...
Jul 8, 2015
WALTHAM, Mass., July 8, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for tradin...
Jul 6, 2015
WALTHAM, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that the ARCHITECT® Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with clinical evaluation as...
May 14, 2015
Net Loss Reduced by 38% and Operating Cash Burn Cut by 42% from First Quarter 2014 Outlook Improved for 2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the first quarter of 2015. "We continue to prepare...
May 7, 2015
WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 14, 2015 at 8:30 a.m. Eastern Time to discuss its Q1 2015 financial results before the market opens. Conference Call Details The conference call may be accessed by ...
Mar 31, 2015
WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorpo...
1
... NextLast
= add release to Briefcase